Skip to main content
NCBI home page
Antimicrobial Agents and Chemotherapy logoLink to Antimicrobial Agents and Chemotherapy
. 1989 Nov;33(11):1998–2003. doi: 10.1128/aac.33.11.1998

In vitro activity of dactimicin, a novel pseudodisaccharide aminoglycoside, compared with activities of other aminoglycosides.

J W Gu 1, H C Neu 1
PMCID: PMC172802  PMID: 2514625

Abstract

The in vitro activity of dactimicin, a new pseudodisaccharide aminoglycoside which possesses a formimidoyl group, was compared with those of gentamicin, tobramycin, and amikacin against 500 isolates. Dactimicin inhibited 90% of isolates from the family Enterobacteriaceae at a concentration of less than or equal to 4 micrograms/ml. It was more active than amikacin against Klebsiella pneumoniae, Serratia marcescens, Citrobacter diversus, Enterobacter agglomerans, Yersinia species, and Salmonella species, with an MIC for 90% of the strains (MIC90) of less than or equal to 4 micrograms/ml. The MIC90s for the Pseudomonas aeruginosa isolates were greater than 128 micrograms/ml. Dactimicin did not inhibit most methicillin-resistant Staphylococcus aureus isolates and coagulase-negative staphylococci but had an MIC50 (MIC for 50% of strains tested) of 2 micrograms/ml against methicillin-susceptible S. aureus isolates and coagulase-negative staphylococci. Dactimicin in combination with piperacillin acted synergistically against 75% of Escherichia coli, K. pneumoniae, S. marcescens, and S. aureus isolates. It exhibited an excellent postantibiotic suppressive effect on E. coli. Dactimicin was active against organisms possessing aminoglycoside-modifying enzymes including AAC(2')-b, AAC(3)-III, -IV, and -V, and AAC(6')-Ia, -Ib, Ic, -II, and -IV but was not active against isolates which contained AAC(3)-I and the bifunctional APH(2")-AAC(6')-I. Its lack of activity against P. aeruginosa appeared to be permeability related since in the presence of EDTA P. aeruginosa was susceptible, as were mutant isolates resistant because of permeability barriers.

Full text

PDF
1998

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Bryan L. E., O'Hara K., Wong S. Lipopolysaccharide changes in impermeability-type aminoglycoside resistance in Pseudomonas aeruginosa. Antimicrob Agents Chemother. 1984 Aug;26(2):250–255. doi: 10.1128/aac.26.2.250. [DOI] [PMC free article] [PubMed] [Google Scholar]
  2. Gomez-Lus R., Marco M. A., Gomez-Lus M. L. Stability of dactimicin to aminoglycoside-modifying enzymes. Drugs Exp Clin Res. 1987;13(12):731–735. [PubMed] [Google Scholar]
  3. Inouye S., Ohba K., Shomura T., Kojima M., Tsuruoka T., Yoshida J., Kato N., Ito M., Amano S., Omoto S. A novel aminoglycoside antibiotic, substance SF-2052. J Antibiot (Tokyo) 1979 Dec;32(12):1355–1356. [PubMed] [Google Scholar]
  4. Matsuhashi Y., Yoshida T., Hara T., Kazuno Y., Inouye S. In vitro and in vivo antibacterial activities of dactimicin, a novel pseudodisaccharide aminoglycoside, compared with those of other aminoglycoside antibiotics. Antimicrob Agents Chemother. 1985 Apr;27(4):589–594. doi: 10.1128/aac.27.4.589. [DOI] [PMC free article] [PubMed] [Google Scholar]
  5. Neu H. C. Antibiotics in the second half of the 1980s. Areas of future development and the effect of new agents on aminoglycoside use. Am J Med. 1986 Jun 30;80(6B):195–203. doi: 10.1016/0002-9343(86)90501-2. [DOI] [PubMed] [Google Scholar]
  6. Pancoast S. J. Aminoglycoside antibiotics in clinical use. Med Clin North Am. 1988 May;72(3):581–612. doi: 10.1016/s0025-7125(16)30760-x. [DOI] [PubMed] [Google Scholar]
  7. Pearson R. D., Steigbigel R. T., Davis H. T., Chapman S. W. Method of reliable determination of minimal lethal antibiotic concentrations. Antimicrob Agents Chemother. 1980 Nov;18(5):699–708. doi: 10.1128/aac.18.5.699. [DOI] [PMC free article] [PubMed] [Google Scholar]
  8. Price K. E. Aminoglycoside research 1975-1985: prospects for development of improved agents. Antimicrob Agents Chemother. 1986 Apr;29(4):543–548. doi: 10.1128/aac.29.4.543. [DOI] [PMC free article] [PubMed] [Google Scholar]
  9. Shimizu K., Kumada T., Hsieh W. C., Chung H. Y., Chong Y., Hare R. S., Miller G. H., Sabatelli F. J., Howard J. Comparison of aminoglycoside resistance patterns in Japan, Formosa, and Korea, Chile, and the United States. Antimicrob Agents Chemother. 1985 Aug;28(2):282–288. doi: 10.1128/aac.28.2.282. [DOI] [PMC free article] [PubMed] [Google Scholar]
  10. Stefani S., Nicoletti G., Russo G., Toscano M. A. First microbiological approach to dactimicin, a novel aminoglycoside antibiotic. Drugs Exp Clin Res. 1987;13(12):727–729. [PubMed] [Google Scholar]
  11. Viano I., Bertelli A. A., Dianzani C. Toxic effects on rabbit kidney cell cultures of a new aminoglycoside. Drugs Exp Clin Res. 1987;13(12):737–739. [PubMed] [Google Scholar]
  12. Zimmermann W. Penetration through the gram-negative cell wall: a co-determinant of the efficacy of beta-lactam antibiotics. Int J Clin Pharmacol Biopharm. 1979 Mar;17(3):131–134. [PubMed] [Google Scholar]

Articles from Antimicrobial Agents and Chemotherapy are provided here courtesy of American Society for Microbiology (ASM)

RESOURCES